Despite advancements in guideline-directed therapy, heart failure readmissions remain high. At the American College of Physicians Internal Medicine Meeting 2025, Shudhanshu Alishetti, MD, outlined how...
Despite advancements in guideline-directed therapy, heart failure readmissions remain high. At the American College of Physicians Internal Medicine Meeting 2025, Shudhanshu Alishetti, MD, outlined how...
Despite advancements in guideline-directed therapy, heart failure readmissions remain high. At the American College of Physicians Internal Medicine Meeting 2025, Shudhanshu Alishetti, MD, outlined how...
Despite advancements in guideline-directed therapy, heart failure readmissions remain high. At the American College of Physicians Internal Medicine Meeting 2025, Shudhanshu Alishetti, MD, outlined how...
Despite advancements in guideline-directed therapy, heart failure readmissions remain high. At the American College of Physicians Internal Medicine Meeting 2025, Shudhanshu Alishetti, MD, outlined how...
Despite advancements in guideline-directed therapy, heart failure readmissions remain high. At the American College of Physicians Internal Medicine Meeting 2025, Shudhanshu Alishetti, MD, outlined how...
Despite advancements in guideline-directed therapy, heart failure readmissions remain high. At the American College of Physicians Internal Medicine Meeting 2025, Shudhanshu Alishetti, MD, outlined how...
Despite advancements in guideline-directed therapy, heart failure readmissions remain high. At the American College of Physicians Internal Medicine Meeting 2025, Shudhanshu Alishetti, MD, outlined how...
Despite advancements in guideline-directed therapy, heart failure readmissions remain high. At the American College of Physicians Internal Medicine Meeting 2025, Shudhanshu Alishetti, MD, outlined how...
In a large, matched-cohort study, patients with coronary artery disease receiving colchicine plus an SGLT2 inhibitor had significantly lower risks of mortality, MACE, ischemic stroke, and atrial...
